Actual Experience (AE) offers an entirely new approach to managing corporate digital supply chains. AE solves a ubiquitous industry-wide problem by quantifying users’ productivity and automatically diagnosing problems. Incorporated in 2009, AE attracted seed investment of £1.4 million. Today, AE’s software services are used by 28 organisations in the UK, US and Germany eg Thomson Reuters, Cisco Systems, Verizon Business, DHL, Capital One and ITV. AE’s top ten customers have approximately 1 million employees in total, and over $300 billion of annual revenues.
Actual Experience was acknowledged for its achievements at the Institution of Engineering and Technology’s (IET’s) 2012 Innovation Awards ceremony. The IET judging panel for the Information Technology category commented: The end user responsiveness of IT systems is crucial to business users and customers connected via the Internet. This entry provides the means to actively manage that human experience and to quickly identify and resolve any issues that affect this.
In November 2013, AE secured a further £4 million equity investment from Henderson and listed on AIM in February 2014.
The founders have developed a novel technology that enables the pharmaceutical and biotechnology industry to identify biomarkers and better select new drugs for diseases such as cancer, autoimmunity and diabetes and help reduce their time to market. Activiomics partners with pharma and biotech using its innovative mass spectrometry-based method to analyse and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.
In March 2011, IP Group provided seed investment to strengthen Activiomics’ ability to grow its partnerships with pharmaceutical and biotechnology companies and to pursue the identification of novel predictive and prognostic markers in oncology.
In September 2012 IP Group made a further investment to carry out an in-house R&D programme to generate new IP, recruit an experienced CEO and establish a commercialisation plan for strengthening its pharma tool offerings by “productising” TIQUAS technology. Industry experienced Chairman Trevor Nicholls was appointed in March 2012.
ApaTech is an orthobiologics company specialising in synthetic bone graft materials.
In 2009 ApaTech was ranked number two in the Times Tech Track 100 Fastest Growing Private Companies listing and received a number of awards including Device Biologics Company of the Year at the Excellence in Medical Technologies and Life Sciences Conference 2009 in recognition of the company’s success in the US orthobiologics market and its outstanding commercial success and leadership.
In both 2007 and 2008 ApaTech received the Research and Development Award at the Tech Track awards ceremony in London, recognising the innovation and ground breaking research which underpinned the successful growth of the company.
ApaTech’s lead product, ACTIFUSE, a new class of bone graft material, is being used in Europe, the United States and other select markets around the World.
ApaTech’s was acquired by Baxter International Inc. in 2010 for a total of up to $330 million.
Retroscreen (RVG) was incorporated in 1988 as a spin-out company from QMUL to commercialise the academic research of Professor John Oxford in the field of retroviruses. RVG’s work has always been demand-led, with RVG initially incorporated to undertake laboratory work at the request of a big pharma. This initial contract led to further studies and RVG continued to conduct laboratory work for some of the world’s leading pharmaceutical companies.
In 2002, RVG expanded from laboratory based studies to clinical challenge trials. In 2006 the company was venture financed by IP Group to allow it to undertake larger studies on a commercial scale. The company was able to demonstrate that the viral challenge model (VCM) could be effective in offering pharmaceutical clients a faster and cost effective route to market for their therapeutics.
Subsequent to further VCM investment, in 2011 RVG moved to QM BioEnterprises, QMUL’s bespoke commercial innovation centre in Whitechapel, where it developed its own dedicated VCM unit. RVG’s scientific team expanded to over twenty who, between them, have significant experience of designing and conducting human challenge studies,
RVG is the only company in the world to operate its VCM that has, to date, been used primarily in the growing market for flu and cold testing, estimated to be sized at approximately £612 million per annum.
In May 2012 RVL listed on AIM raising £15 million, and in May 2013 raised a further £25 million from existing and new investors.
The company is well placed to continue its commitment to working with scientists and industry to create the next generation of drugs and vaccines for a number of important global respiratory diseases.